United-Guardian Inc Dossier - Source-backed chat

United-Guardian Inc

UGNASDAQ

SectorConsumer Staples

IndustryPersonal Products

Beta (adjusted)0.96

Intrinsic Value $7.56median of 3 methodsbased on filings through 30 Jun 2026

Market Price $7.16Price as of 30 Sep 2026

Near fair valueIntrinsic value is 6% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $32.9M

Enterprise Value $30.5M

Shares Outstanding 4.6M diluted

Moat Rating Wide

Next Earnings Date6 Nov 2026

Last ex-dividend28 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

United-Guardian, Inc. (NASDAQ:UG) is a highly specialized developer and manufacturer of niche cosmetic ingredients, pharmaceuticals, and medical lubricants. Following a challenging FY 2025 where net sales declined 13% due to distributor destocking and weak demand in China, Q1 2026 results demonstrate a strong operational rebound. Net sales rose 16% to $2.87M and net income surged 46% to $0.82M, driven by a 24% increase in Renacidin sales and a 21% recovery in cosmetic ingredients as Ashland Specialty Ingredients normalized inventory levels. While the company's high dividend yield (historically ~7%) and debt-free balance sheet provide solid downside protection, long-term growth is constrained by intense competition from local Asian cosmetic producers and rising Medicare Part D rebate liabilities that will phase in through 2031. Consequently, a Hold recommendation is warranted as the company transitions from stabilizing its core business to executing its new healthcare practitioner outreach and sexual wellness product lines.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is triggered by renewed distributor overstocking or severe pricing pressure from local Chinese cosmetic ingredient manufacturers, causing the cosmetic segment to resume its decline. Additionally, Renacidin sales growth stalls due to failure to expand practitioner awareness, while rising Medicare Part D rebate liabilities compress pharmaceutical margins faster than anticipated, forcing a reduction in the annual dividend payout.

Base CaseCentral scenario

The base case assumes that cosmetic ingredient sales continue to stabilize as distributor inventory levels normalize, while Renacidin maintains steady mid-single-digit growth supported by targeted marketing to healthcare practitioners. The company successfully commercializes its Natrajel line in the sexual wellness segment, offsetting competitive pressures in China. Operating margins remain healthy at around 20-22%, and the company continues its 31-year track record of paying consistent dividends.

Bull CaseUpside scenario

United-Guardian's niche specialty chemical focus—particularly in lubricants and personal care ingredients—provides a defensible moat with stable, recurring demand from established industrial and cosmetic clients, supporting consistent revenue generation and pricing power over the near term.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong balance sheet with zero debt and a significant cash position relative to its micro-cap market capitalization.
Long-standing history of returning capital to shareholders, marking 31 consecutive years of cash dividend payments as of 2026.
High-margin pharmaceutical business led by Renacidin, which is experiencing strong demand and benefiting from recent insurance formulary gains.
Successful resolution of the cosmetic distributor inventory imbalance, with Ashland Specialty Ingredients' purchases rebounding 45% in Q1 2026.

Key Investment Risks

High customer concentration, with three pharmaceutical wholesalers and one cosmetic distributor historically accounting for over 70% of gross sales.
Intense competition in the cosmetic ingredients segment from low-cost local producers, particularly in China.
Regulatory and margin risks associated with the Medicare Part D program, which will gradually increase rebate liabilities for Renacidin through 2031.

Thesis Invalidation Triggers

A material reduction or suspension of the company's annual dividend, which would severely impact its appeal to income-focused retail investors.
Loss of or significant order reductions from key distributors such as Ashland Specialty Ingredients or major pharmaceutical wholesalers.
Failure of the healthcare practitioner outreach campaign to sustain Renacidin sales growth.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.